Loading...

Ginkgo Bioworks Holdings, Inc. WT

DNA-WTNYSE
HealthcareBiotechnology
$0.27
$-0.01(-2.76%)

Ginkgo Bioworks Holdings, Inc. WT DNA-WT Peers

See (DNA-WT) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
DNA-WT$0.27-2.76%18.7BN/AN/AN/A
VRTX$446.50+0.24%114.7B-117.50-$3.80N/A
REGN$487.86-0.60%51.8B12.39$39.36+0.36%
SGEN$228.74-0.07%43.2B-57.19-$4.00N/A
ALNY$303.73-0.77%39.6B-144.63-$2.10N/A
ARGX$576.61-1.37%35.2B35.20$16.38N/A
BNTX$115.62+2.23%27.8B-32.30-$3.58N/A
BGNE$184.71+0.49%20.2B-22.55-$8.19N/A
RPRX$33.29+0.09%18.7B13.59$2.45+2.58%
SMMT$20.62+16.33%15.2B-60.65-$0.34N/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

DNA-WT vs VRTX Comparison

DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, VRTX has a market cap of 114.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while VRTX trades at $446.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is -117.50. In terms of profitability, DNA-WT's ROE is -0.63%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, DNA-WT is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.

Stock Price Comparison

Loading...

Frequently Asked Questions